Last reviewed · How we verify
F901318 pharmacokinetics
At a glance
| Generic name | F901318 pharmacokinetics |
|---|---|
| Also known as | metabolism |
| Sponsor | F2G Biotech GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment (PHASE1)
- A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment (PHASE1)
- A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim (PHASE1)
- Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim (PHASE1)
- Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects (PHASE1)
- Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia (PHASE1, PHASE2)
- Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients (PHASE1, PHASE2)
- Pharmacokinetics of IV Formulation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F901318 pharmacokinetics CI brief — competitive landscape report
- F901318 pharmacokinetics updates RSS · CI watch RSS
- F2G Biotech GmbH portfolio CI